Vis enkel innførsel

dc.contributor.authorLi, Pengfei
dc.contributor.authorHoppmann, Susan
dc.contributor.authorDu, Ping
dc.contributor.authorLi, Huiling
dc.contributor.authorEvans, Paul
dc.contributor.authorMoestue, Siver Andreas
dc.contributor.authorYu, Weiyue
dc.contributor.authorDong, Fang
dc.contributor.authorLiu, Hongchuan
dc.contributor.authorLiu, Lihong
dc.date.accessioned2017-06-02T08:26:29Z
dc.date.available2017-06-02T08:26:29Z
dc.date.created2017-03-13T09:14:35Z
dc.date.issued2017
dc.identifier.issn0301-5629
dc.identifier.urihttp://hdl.handle.net/11250/2444211
dc.description.abstractSonazoid is an ultrasound contrast agent based on microbubbles (MB) containing perfluorobutane (PFB) gas. Sonazoid is approved in Japan, Korea and Norway for contrast-enhanced ultrasonography of focal liver lesions and focal breast lesions (Japan only). The objective of this study was to determine the pharmacokinetics (PKs) and safety of Sonazoid in Chinese healthy volunteers (HVs) and to evaluate the potential for ethnic differences in PKs between Chinese and Caucasian HVs. Sonazoid was administered as an intra-venous bolus injection at the clinical dose of 0.12 μL or 0.60 μL MB/kg body weight to two groups of eight Chinese HVs. Expired air and blood samples were collected and analyzed using a validated gas chromatographic tandem mass spectrometry method, and the main PK parameters were calculated. The highest PFB concentrations in blood were observed shortly after intra-venous administration of Sonazoid, and elimination of PFB was rapid. In the 0.12 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for only 10 to 15 min post-injection. In the 0.60 μL MB/kg body weight cohort, PFB concentrations above the limit of quantification were observed for 60 min post-injection, and the shape of the elimination curve suggested a biphasic elimination profile. The maximum observed concentration (Cmax) values of PFB in blood were 2.3 ± 1.1 and 19.1 ± 9.2 ng/g for the 0.12 and 0.60 μL MB/kg body weight dose groups (mean ± standard deviation). Area under the curve values were 10.1 ± 2.7 and 90.1 ± 38.3 ng × min/g for the 0.12 and 0.60 μL MB/kg body weight dose groups. Cmax values of PFB in exhaled air were 0.35 ± 0.2 and 2.4 ± 0.7 ng/mL for the 0.12 and 0.60 μL MB/kg body weight dose groups. Assessment of laboratory parameters, vital signs, oxygen saturation and electrocardiograms revealed no changes indicative of a concern. The PK profile and safety data generated in the Chinese HVs were comparable to previous data for Caucasian HVs.nb_NO
dc.language.isoengnb_NO
dc.publisherElseviernb_NO
dc.relation.urihttp://www.umbjournal.org/article/S0301-5629(17)30009-1/pdf
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titlePharmacokinetics of Perfluorobutane after Intra-venous Bolus Injection of Sonazoid in Healthy Chinese Volunteers.nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.journalUltrasound in Medicine and Biologynb_NO
dc.identifier.doi10.1016/j.ultrasmedbio.2017.01.003
dc.identifier.cristin1457663
dc.relation.projectNorges forskningsråd: 239940nb_NO
dc.description.localcode© 2017 The Authors. Published by Elsevier Inc. on behalf of World Federation for Ultrasound in Medicine & Biology. Printed in the USA. This is an open access article under the CC BY-NC-ND licensenb_NO
cristin.unitcode194,65,10,0
cristin.unitnameInstitutt for laboratoriemedisin, barne- og kvinnesykdommer
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal